Brain speed test could transform sickle cell care
NCT ID NCT07168447
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study examines how regular blood transfusions (exchange transfusions) affect thinking speed in adults with severe sickle cell disease. Researchers will test 85 participants remotely using a simple symbol-matching task and other cognitive assessments at different points in their transfusion cycle. The goal is to see if processing speed can be a reliable marker for monitoring brain health in this condition.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors use a simple thinking-speed test to monitor brain health in sickle cell patients and guide future treatments.
- What could go wrong
- This is an early observational study, not a treatment trial. It may not find clear links, and results might not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 85 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Dec 2025
An estimate. Start dates often move.
- Expected to finish
-
Nov 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population consists of adults aged 18 years or older with severe sickle cell disease (SS or Sβ0) who are enrolled in a regular monthly transfusion exchange program. Participants must not be institutionalized, must have no known dementia or severe aphasia, and must be able to communicate in French. They must also be affiliated with a social security system. Excluded are individuals with severe comorbidities that could interfere with short-term follow-up, those with known psychiatric disorders, participants in other ongoing clinical studies with exclusion periods, individuals lacking adequate computer equipment for remote assessments, and vulnerable patients under legal protection such as guardianship or curatorship. This population allows evaluation of cognitive processing speed and other neuropsychological outcomes in a controlled, transfusion-managed cohort of adult sickle cell patients.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adults (≥18 years) with severe sickle cell disease (SS or Sβ0). * Enrolled in a regular monthly transfusion exchange program. * Not institutionalized. * No known dementia. * No severe aphasia. * Affiliated with or beneficiary of a social security system. Exclusion criteria: * Insufficient mastery of spoken French. * Severe comorbidities preventing short-term follow-up. * Known psychiatric disorders. * Participation in another clinical study with ongoing exclusion periods. * Lack of adequate computer equipment (minimum 11-inch screen and internet connection). * Vulnerable patients under legal protection (guardianship or curatorship).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic neurological deficiency are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
6 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Assistance Publique - Hôpitaux de Paris Hôpital Avicenne
Bobigny, Île-de-France Region, 93000, France
-
Assistance Publique - Hôpitaux de Paris Hôpital Necker
Paris, Île-de-France Region, 75015, France
-
Centre Hospitalier Saint-Denis
Saint-Denis, Île-de-France Region, 93200, France
-
GHU Paris Psychiatrie et Neurosciences - Hôpital Sainte-Anne
Paris, Île-de-France Region, 75014, France
-
Hôpital Henri Mondor
Créteil, Île-de-France Region, 94000, France
-
Hôpital Kremlin-Bicêtre
Le Kremlin-Bicêtre, Île-de-France Region, 94 275, France